The association between extrinsic activated protein C resistance and venous thromboembolism in women

Contraception

Volumn 66, Issue 5, 2002, Pages 297-304

  Heinemann, L A J ^a   Kluft, C ^b   Spannagl, M ^c   De Maat, M P M ^b  

^a Health Research Berlin   (Germany)

^b TNO   (Netherlands)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

APC resistance; Case control study; Epidemiology; Venous thromboembolism

Indexed keywords

ACTIVATED PROTEIN C; ALPHA 2 MACROGLOBULIN; BLOOD CLOTTING FACTOR 5 LEIDEN; THROMBIN; BLOOD CLOTTING FACTOR 5; ORAL CONTRACEPTIVE AGENT; PROTEIN C;

ADULT; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; HUMAN; INTERVIEW; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MUTATION; POPULATION RESEARCH; PRIMARY HEALTH CARE; THROMBOEMBOLISM; ADOLESCENT; BLOOD; CHEMICALLY INDUCED DISORDER; GENETICS; METABOLISM; MIDDLE AGED; NETHERLANDS; QUESTIONNAIRE; VEIN THROMBOSIS;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL, COMBINED; FACTOR V; FEMALE; HUMANS; MIDDLE AGED; NETHERLANDS; PROTEIN C; QUESTIONNAIRES; VENOUS THROMBOSIS;

EID: 0036851156     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(02)00388-8     Document Type: Article

References (26)

1. Bertina R.M., Koelman B.P., Koster T., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 369:1994;64-67.
2. Dahlbäck B., Carlson M., Svensson P.J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C prediction of a cofactor to activated protein C . Proc Natl Acad Sci USA. 90:1993;1004-1008.
3. De Visser M.C.H., Rosendaal F.R., Bertina R.M. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood. 93:1999;1271-1276.
4. Curvers J., Thomassen M.C., Nicolaes G.A., et al. Acquired APC resistance and oral contraceptives differences between two functional tests . Br J Haematol. 105:1999;88-94.
5. Kluft C., Meijer P., Gram J., Jespersen J. Acquired activated protein-C resistance. (letter) Lancet. 353:1999;1882.
6. Rosing J., Tans G., Nicolaes G.A.F., et al. Oral contraceptives and venous thrombosis different sensitivities to activated protein C in women using second- and third-generation oral contraceptives . Br J Haematol. 97:1997;23-38.
7. Kluft C., de Maat M.P.M., Heinemann L.A.J., Spannagl M., Schramm W. Importance of levonorgestrel dose in oral contraceptives for effects on coagulation. Lancet. 354:1999;832-833.
8. Meijers J.C.M., Middeldorp S., Tekelenburg W., et al. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down-regulation of fibrinolysis. A randomized cross-over study of two low-dose oral contraceptives. Thromb Haemost. 84:2000;9-14.
9. Middeldorp S., Meijers J.C.M., Van Den Ende A.E., et al. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives. Thromb Haemost. 84:2000;4-8.
10. Rosing J., Middeldorp S., Curvers J., et al. Low-dose oral contraceptives and acquired resistance to activated protein C a randomized cross-over study . Lancet. 354:1999;2036-2040.
11. Tans G., Curvers J., Middeldorp S., et al. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost. 84:2000;15-21.
12. Heinemann L.A.J. The changing scene - an unnecessary pill crisis. Hum Reprod Update. 5:1999;746-755.
13. Schramm W., Heinemann L.A.J. Oral contraceptives and venous thromboembolism acquired APC resistance? Br J Haematol. 98:1997;491-492.
14. Schramm W., Heinemann L.A.J., Spannagl M., Dick A., Assmann A. Die BAyerischen Thrombo-Embolie-Risiko Kohortenstudie (BATER). Studienprotokoll, Stand der Untersuchung und erste Ergebnisse. Dtsch Med Wschr. 125:2000;2-6.
15. Heinemann L.A.J., Assmann A., Spannagl M., et al. Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism. Contraception. 58:1998;321-322.
16. Kluft C. A rebuttal - oral contraceptives, and venous thrombosis. Thromb Haemost. 85:2001;934-936.
17. Nicolaes G.A.F., Thomassen M.C.L.G.D., Tans G., Rosing J., Hemker H.C. Effect of activated protein C on thrombin generation, and on the thrombin potential in plasma of normal, and APC-resistant individuals. Blood Coagul Fibrinol. 8:1997;28-38.
18. Tans G., Rosendaal F.R., Curvers J., Thomassen M.C.L.G.D., Bertina R., Rosing J. APC resistance determined with the endogenous thrombin generation potential is associated with venous thrombosis a blinded evaluation . (abstract 640) Thromb Haemost. 82:(suppl):1999;202-203.
19. Zotz R.B., Gerhardt A., Kluft C., Ruediger E. Activated protein C sensitivity ratio based on the endogenous thrombin potential is not a risk factor for pregnancy-associated venous thromboembolism. (abstract) Blood. 96:2000;257a.
20. Grand'Maison A., Douketis J., Bates S.M., Johnston M., Ginsberg J.S. Endogenous thrombin potential, and the risk of venous thromboembolism. (abstract) Blood. 96:2000;95b.
21. Hoibraaten E., Mowinckel M.C., de Ronde H., Bertina R.M. Hormone replacement therapy (HRT) induces acquired resistance to activated protein C (APC) results from a randomized, double-blind, clinical trial . (abstract) Blood. 96:2000;816a.
22. Crook D., Godsland I. Safety evaluation of modern oral contraceptives. Effects of lipoproteins and carbohydrate metabolism. Contraception. 57:1998;189-201.
23. Griffin J.H., Petäjä J. Activated protein C resistance. Schafer A.I., Molecular mechanisms of hypercoagulable states. 1997;102-123 Landes Bioscience, Austin, TX.
24. Kojima K., Fernández J.A., Banka C.L., et al. High density lipoprotein enhancement of antithrombotic protein C pathway. (abstract) Blood. 88:(suppl):1996;523a.
25. Fernández J.A., Kojima K., Hackeng T.M., et al. Cardiolipin, a protein C pathway cofactor implications for anticardiolipin antibody syndrome . (abstract) Thromb Haemost. 73:1995;1263.
26. Vandenbrouke J.P., Koster T., Briet E. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet. 344:1994;1453-1457.